Bernd Meibohm, PhD, FCP


Bernd Meibohm, PhD, FCP

Professor & Associate Dean
Graduate Programs and Research

Office location

5p Crowe Research Building
874 Union Avenue
Memphis, TN 38163
Tel: (901) 448 - 1206
Fax: (901) 448 - 6940
Email: bmeibohm@uthsc.edu

Current Office Hours

by appointment

CURRICULUM VITAE

Degree

Professional Experience

Honors and Awards

  • Honored for Outstanding Performance as Pharmacy Student, Secretary of Education and Art of the State of Lower Saxony, 1988
  • Postdoctoral Research Fellowship, German Research Foundation (Deutsche Forschungsgemeinschaft DFG), 1995-1997
  • Poster Presentation Award, 10th Annual Research Showcase, University of Florida, 1997
  • Teacher of the Year Award, College of Pharmacy, University of South Carolina, 1999
  • AAPS New Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, 2000
  • Fellow of the American College of Clinical Pharmacology (ACCP), 2002
  • Excellence in Teaching Award - UTHSC Student Government Association Executive Council, 2005

RESEARCH INTERESTS

Dr. Meibohm’s research is focused on the investigation of the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs with special emphasis on PK/PD-correlations.

Pharmacokinetic/pharmacodynamic (PK/PD)-modeling bridges the gap between dynamic dose-concentration relationships and static concentration-effect relationships of drugs. By combining information provided by pharmacokinetics and by pharmacodynamics, it facilitates the description and prediction of the time course of drug effects that are resulting from a certain dosing regimen. The application of these PK/PD-modeling concepts has been identified as beneficial in all phases of preclinical and clinical drug development as well as in applied clinical pharmacotherapy, where it provides a more rational basis for patient-specific dosage individualization.

Thus, the ultimate goal of the research in Dr. Meibohm’s lab is to contribute to the optimization of dosing regimens for increased efficacy and reduced toxicity and to modulate pharmacotherapy according to the needs of the individual patient.

Special areas of interest are:

  • Pharmacokinetics and pharmacodynamics of cardiovascular and anesthetic drugs in pediatric patients and their dependency on developmental changes.
  • Pharmacokinetics and pharmacodynamics of therapeutics for asthma and chronic obstructive pulmonary disease (COPD), with focus on corticosteroids and other anti-inflammatory agents.
  • Application of pharmacometrics and quantitative pharmacology concepts in preclinical and clinical drug development
 

This includes the application of the following research techniques:

  • Evaluation of the pharmacokinetic properties of investigational as well as marketed drugs or dosage forms in animal models, healthy volunteers or various patient subpopulations.
  • Participation in the planning, conduct, and analysis of clinical trials.
  • Development and validation of bioanalytical assays to quantify drug concentrations in biological fluids.
  • Application of molecular biology research techniques for DNA, RNA and protein analysis relevant to drug response.
  • Identification and validation of surrogate endpoints as measure for the pharmacologic activity of drugs.
  • Computer-based mathematical modeling and simulation of the correlation between the pharmacokinetics and pharmacodynamics of drugs (PK/PD-modeling).
  • Application of population approaches in pharmacokinetic and pharmacodynamic data analysis.

Dr. Meibohm’s research group is actively collaborating with researchers and clinicians at the University of Tennessee Colleges of Pharmacy, Medicine and Nursing, LeBonheur Children's Medical Center, Memphis, TN, St. Jude Children's Research Hospital, Memphis, TN, The Children's Hospital of Philadelphia, Philadelphia, PAWake Forest University Medical Center, Winston-Salem, NC, the University of Düsseldorf School of Pharmacy, Düsseldorf, Germany, Metrum Institute, Augusta, ME, the Institute for Applied Healthcare Sciences, Hamburg, Germany, and in the pharmaceutical industry.

Current collaborative research projects include:

Inflammatory Lung Disease

  • Evaluation of the effect of genetic variations on the prevalence, severity, and pharmacotherapy of inflammatory pulmonary diseases, e.g. chronic obstructive pulmonary disease (COPD).
  • Identification and validation of biomarkers for pulmonary decline
  • Gene expression profiling for the identification of biomarkers for inflammation, disease progression and response to pharmacotherapeutic intervention in obstructive lung disease.

Pediatric Pharmacotherapy

  • Evaluation of the effect of developmental changes on the disposition of and response to investigational and clinically used drugs in pediatric patients, with specific focus on hepatic drug transporters.
  • Investigation of the pharmacokinetics and pharmacodynamics of medications used in neonatal and pediatric pharmacotherapy, including population PK/PD modeling and simulation to optimize dosing strategies and trial designs.

Drug Development

  • Pharmacokinetic and pharmacodynamic characterization including PK/PD-modeling of the investigational drugs, especially biotechnologically derived drug products.
  • Preclinical pharmacokinetic and pharmacodynamic evaluation and optimization of novel anti-infectives against tuberculosis.
  • Pharmacokinetic evaluation of dosage forms of oligonucleotide drugs in preclinical and clinical drug development.

Editorial Appointments

  • Section Editor – Pharmacokinetics and Pharmacodynamics – The Journal of Clinical Pharmacology, American College of Clinical Pharmacology, Jul 2003 – present.
  • Editorial Board - The Journal of Pediatric Pharmacology and Therapeutics, Pediatric Pharmacy Advocacy Group, Jun 2000 – present.
  • Editorial Board – The Journal of Clinical Pharmacology, American College of Clinical Pharmacology, Jan 2003 – Jul 2003.
  • Editorial Board – Die Pharmazie, Govi-Verlag, Eschborn, Germany, Jan 2004 – present.

SELECTED PUBLICATIONS

  1. Meibohm, B, Wegener, S: Mexiletine-Theophylline-Interaction. Krankenhauspharmazie 13 (1992), p. 331-333
  2. Steffens, KJ, Schreiber, R, Meibohm, B: TPN-Regimes and Parenteral Fat Emulsions. Krankenhauspharmazie 13 (1992), p. 426-430
  3. Rohatagi, S, Bye, A, Falcoz, C, Mackie, AE, Meibohm, B, Möllmann, H, Derendorf, H: Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate. Journal of Clinical Pharmacology 36 (1996), p. 938-941
  4. Meibohm, B, Hochhaus, G, Rohatagi, S, Möllmann, H, Barth, J, Wagner, M, Krieg, M, Stöckmann, R, Derendorf, H: Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. Journal of Clinical Pharmacology 37 (1997), p. 704-710
  5. Meibohm, B, Derendorf, H: Basic Concepts of Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling. International Journal of Clinical Pharmacology and Therapeutics 35 (1997), p. 401-413
  6. Derendorf, H, Möllmann, H, Hochhaus, G, Meibohm, B, Barth, J: Clinical PK/PD-Modeling as a Tool in Drug Development of Corticosteroids. International Journal of Clinical Pharmacology and Therapeutics 35 (1997), p. 481-488
  7. Möllmann, H, Derendorf, H, Barth, J, Meibohm, B, Wagner, M, Krieg, M, Köller, J, Hochhaus, G: Pharmacokinetic/Pharmacodynamic Evaluation of the Systemic Effects of Flunisolide after Inhalation. Journal of Clinical Pharmacology 37 (1997), p. 893-903
  8. Meibohm, B, Garms, T, Meier, K, Melzer, S, Schwarz, S: Pharmacoeconomic Benefit of a Patient Oriented Automated Drug Distribution System combined with Intensive Advisory Services. Journal of Applied Therapeutics 1 (1997), p. 343-349.
  9. Möllmann, H, Wagner, M, Meibohm, B, Hochhaus, G, Barth, J, Stöckmann, R, Krieg, M, Weisser, H, Falcoz, C, Derendorf, H: Pharmacokinetic and Pharmacodynamic Evaluation of Fluticasone Propionate after Inhaled Administration. European Journal of Clinical Pharmacology 53 (1998), p. 459-467
  10. Derendorf, H, Hochhaus, G, Meibohm, B, Möllmann, H, Barth, J. Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology 101 (1998), p. S440-S446.
  11. Meibohm, B, Möllmann, H, Wagner, M, Hochhaus, G, Möllmann, A, Derendorf, H: The Clinical Pharmacology of Fluticasone Propionate. Reviews in Contemporary Pharmacotherapy 9 (1998), p. 535-549.
  12. Derendorf, H, Meibohm, B: Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives. Pharmaceutical Research 16 (1999), p. 176-185.
  13. Meibohm, B, Derendorf, H, Möllmann, H, Fröehlich, P, Tromm, A, Wagner, M, Homrighausen, S, Krieg, M, Hochhaus, G: Mechanism-Based PK/PD Model for the Lymphocytopenia Induced by Endogenous and Exogenous Corticosteroids. International Journal of Clinical Pharmacology and Therapeutics 37 (1999), p. 367-376.
  14. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Wagner, M, Krieg, M, Stöckmann, R, Derendorf, H: A PK/PD-Approach to Predict the Cumulative Cortisol Suppression of Inhaled Corticosteroids. Journal of Pharmacokinetics and Biopharmaceutics 27 (1999), p. 127-147.
  15. Beierle, I, Meibohm, B, Derendorf, H: Gender Differences in Pharmacokinetics and Pharmacodynamics. International Journal of Clinical Pharmacology and Therapeutics 37 (1999), p. 529-547.
  16. Derendorf, H, Hochhaus, G, Krishnaswami, S, Meibohm, B, Möllmann, H. Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. Pharmazie 55 (2000), p. 223-7
  17. Meibohm, B, Zhang, W, Beierle, I, Meyer, MC. Epistaxis associated with elevation of INR in a patient switched to generic warfarin – another view. Pharmacotherapy 20 (2000), p. 866-71
  18. Läer, S, Wauer, I, Behn, F, Scholz, H, Mir, TS, Weil, J, Meibohm, B, Hulpke-Wette, M. Pharmacokinetics of sotalol in different age groups of children with tachycardia. Journal of Pediatric Pharmacology and Therapeutics 6 (2001), p. 50-9
  19. Läer, S, Meibohm, B, Mir, TS, Hulpke-Wette, M. Termination of automatic atrial tachycardia in an infant by adequate sotalol dosing: Indication of clinically relevant age-dependent pharmacokinetics of sotalol. European Journal of Clinical Pharmacology 57 (2001), p. 181-2
  20. Meibohm, B, Derendorf, H. Pharmacokinetic/pharmacodynamic studies in drug product development. Journal of Pharmaceutical Sciences 91 (2002), p.18-31.
  21. Meibohm, B, Beierle, I, Derendorf, H: How important are gender differences in pharmacokinetics ? Clinical Pharmacokinetics 41 (2002), p. 329-342.
  22. Läer, S, Behn, F, Scholz, H, Mir, TS, Eiselt, M, Venske, A, Meibohm, B, Weil, J. ß-Receptor blocker therapy in pediatric patients with congestive heart failure: A study with carvedilol investigating clinical, pharmacokinetic and pharmacogenetic parameters. American Heart Journal 143 (2002), p. 916-922.
  23. Song P, Li S, Meibohm B, Gaber AO, Honaker MR, Kotb M, and Yates CR. Detection of MDR1 single nucleotide polymorphisms (SNPs) C3435T and G2677T using real-time PCR. AAPS PharmSci 4 (2002), article 29.
  24. Yates, CR, Zhang, W, Song, P, Gaber, AO, Kotb, M, Honaker, MR, Alloway, RR, Meibohm, B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 43 (2003), 555-564.
  25. Gupta, M, Song, P, Yates, CR, Meibohm, B. A real-time PCR genotyping assay for CXCR2 polymorphisms. Clin Chim Acta 341(2004), 93-100.
  26. Tang, L, Persky, AM, Hochhaus, G, Meibohm, B. Pharmacokinetic Aspects of Biotechnology Products. J Pharm Sci 93 (2004), 2184-2204.
  27. Dirks, NL, Huth, B, Yates, CR, Meibohm, B. Pharmacokinetics of Immunosuppressants: A Perspective on Ethnic Differences. Int J Clin Pharmacol Ther 42 (2004), 701-718.
  28. Sharma, A, Pibarot, P, Pilote, S, Dumesnil, JG, Arsenault, M, Bélanger, PM, Meibohm, B, Hamelin, BA. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther 313 (2005), 1172-81.
  29. Song, P, Meibohm, B, Yates, CR. LC/MS/MS in Drug Development: Targeting the Brain. Biotechniques 38 (2005), S19-S23
  30. Gupta, M, Kovar, A, Meibohm, B. The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. Journal of Clinical Pharmacology 45 (2005), 987-1003.
  31. Gupta, M, Yates, CR, Meibohm, B. SYBR Green-Based Real-Time PCR Allelic Discrimination Assay for ß2-Adrenergic Receptor Polymorphisms. Analytical Biochemistry 344 (2005), 292-294.
  32. Meibohm, B, Läer, S, Panetta, JC, Barrett, JS. Population Pharmacokinetic Studies in Pediatrics: Issues in Design and Analysis. AAPS Journal 7 (2005), Article 48, E475-487.
  33. Läer, S, Elshoff, JP, Meibohm, B, Weil, J, Mir, TS, Zhang, W, Hulpke-Wette, M. Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol based on Population Pharmacokinetics and Pharmacodynamics in Children with Supraventricular Tachycardia. Journal of the American College of Cardiology 46 (2005), 1322-1330.
  34. Christensen, ML, Meibohm, B, Capparelli, EV, Velasquez-Meyer, P, Burghen , GA , Tamborlane , WV. Single and multiple dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. Journal of Clinical Pharmacology 45 (2005), 1137-1144.
  35. Song, P, Lamba, JK, Zhang, L. Schuetz, EG, Shukla, N, Meibohm, B, Yates, CR. G2677T and G3435T Genotype and Haplotype are Associated with Hepatic ABCB1 (MDR1) Expression. Journal of Clinical Pharmacology 46 (2006), 373-379.
  36. Chen, ML, Straughn, AB, Sadrieh, N, Meyer, M, Faustino, PJ, Ciavarrella, AB, Meibohm, B, Yates, CR, Hussain, AS. The Effect of Sorbitol on Bioavailability and Bioequivalence: Implication with Common Excipients. Pharmaceutical Research (in press).
  37. Mehrotra, N, Gupta, M, Kovar, A, Meibohm, B. The Role of Pharmacokinetics and Pharmacodynamics in Phosphodiesterase-5 Inhibitor Therapy. Internal Journal of Impotence Research (in press).

Book Chapters

  1. Meibohm, B: Antiarrhythmics (in German). In: ADKA-Committee for Clinical Pharmacy (Eds.): Praxis of Clinical Pharmacy. Vol. I: Clinical Pharmacokinetics. Deutscher Apotheker Verlag, Stuttgart 1992, ISBN 3-7692-1478-1, p. 128-150.
  2. Meibohm, B, Derendorf H: Pharmacokinetics and Pharmacodynamics of Biotechnology Drugs (in German). In: Müller, RH, Kayser, O (Eds.): Pharmazeutische Biotechnologie. WVG Wissenschaftliche Verlagsgesellschaft, Stuttgart 2000, ISBN 3-8047-1768-3, p. 103-124. Translated into Polish: Biotechnologia Farmaceutyczna, Wydawnictwo Lekarskie PZWL, Warszawa 2003, ISBN 83-200-2751-9, p. 91-110.
  3. Meibohm, B: Coronary Heart Disease. In: Schneemann, H (Ed.): Handbook of Applied Pharmacotherapy, Springer, Berlin 2001, ISBN 3-540-41356-1, p. 169-191.
  4. Meibohm, B: Peripheral Vascular Disease. In: Schneemann, H (Ed.): Handbook of Applied Pharmacotherapy, Springer, Berlin 2001, ISBN 3-540-41356-1, p. 193-205.
  5. Meibohm, B: Theophylline. In: Schoenwald, RD (Ed.): Pharmacokinetics in Drug Discovery and Development, CRC Press, Boca Raton 2002, ISBN 1-56676-973-6, p. 201-229.
  6. Yates, CR, Meibohm, B. Pharmacokinetics. In: Gourley, DR, Eoff, JC (Eds.): APhA’s Complete Review for Pharmacy, Castle Connolly 2004, ISBN 0-9723076-3, p. 109-134.
  7. Meibohm, B, Derendorf H: Pharmacokinetics and Pharmacodynamics of Biotech Drugs. In: Kayser, O, Müller, RH (Eds.): Pharmaceutical Biotechnology, Wiley-VCH, Weinheim 2004, ISBN 3-527-30554-8, p. 147-172.
  8. Kovar, A, Meibohm, B. Drug Development in Oncology. In: Bonate, P, Howard, D (Eds.): Pharmacokinetics in Drug Development: An Industrial Perspective, AAPS Press, Alexandria , VA 2004, ISBN 0-9711767-3-6, p. 281-303.
  9. Meibohm, B: Pharmacokinetics of Protein- and Nucleotide-Based Drugs. In: Mahato, RI (Ed.): Biomaterials-Based Delivery and Biocompatibility of Proteins and Nucleic Acids, CRC Press, Boca Raton, Fl, ISBN 0-8493-2334-7, p. 275-294.
  10. Meibohm, B, Derendorf H: Pharmacokinetics and Pharmacodynamics of Biotech Drugs. In: Meyers, RA (Ed.): Encyclopedia of Molecular Cell Biology and Molecular Medicine, 2nd Edition. Volume 10, Wiley-VCH, Weinheim 2005, ISBN 3-527-30552-1, p. 211-241.
  11. Meibohm, B, Evans, WE: Clinical Pharmacodynamics & Pharmacokinetics. In: Helms, RA, Quan, DJ, Herfindal ET, Gourley, DR: Textbook of Therapeutics: Drug and Disease Management, 8th Ed., Lippincott Williams Wilkins 2006, ISBN 0-7817-5734, p. 1-31.

Abstracts

  1. Meibohm, B, Führer, C, Kleine, P: Investigations on the Stereoselective Pharmacokinetics of Mexiletine. European Journal of Pharmaceutical Sciences 2 (1994), p. 114.
  2. Meibohm, B, Garms, T, Meier, K, Melzer, S: Pharmacoeconomic Benefit of the Implementation of a Patient Oriented Automated Drug Distribution System in Combination with Intensive Advisory Services. European Journal of Clinical Pharmacology 48 (1995), p. A409.
  3. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Modulation of Lymphocyte Count in Blood by the Circadian Rhythm of Endogenous Cortisol. Journal of Clinical Pharmacology 36 (1996), p. 853.
  4. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Cumulative Cortisol Suppression as a Measure of the Systemic Effect of Inhaled Corticosteroids. Journal of Clinical Pharmacology 36 (1996), p. 854.
  5. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Circadian Rhythm of Lymphocytes in Blood and its Interrelationship to Endogenous Cortisol. Pharmaceutical Research 13 (1996), (suppl.), p. 446.
  6. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Quantification of Cortisol Suppression as a Measure for the Cumulative Systemic Effect of Corticosteroids. Pharmaceutical Research 13 (1996), (suppl.), p. 446.
  7. Meibohm, B, Hochhaus, G, Derendorf, H: Time Dependency of the Pharmacologic Response to Glucocorticoids. Clinical Pharmacology and Therapeutics 61 (1997), p. 155.
  8. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: A Pharmacokinetic/Pharmacodynamic Approach for Quantifying the Systemic Activity of Inhaled Corticosteroids. Pharmacotherapy 17 (1997), p.195.
  9. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: A PK/PD-Approach to Assess the Systemic Activity of Inhaled Corticosteroids as Cumulative Cortisol Suppression. Pharmazie 52 (1997), p. S28.
  10. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: PK/PD-Modeling of the Circadian Rhythm of the Lymphocyte Count in Blood Modulated by Endogenous Cortisol. Pharmazie 52 (1997), p. S28.
  11. Derendorf, H, Hochhaus, G, Meibohm, B, Möllmann, H, Barth, J: Pharmacokinetics and Pharmacodynamics of Soft Corticosteroids for Inhalation. Pharmazie 52 (1997), p. S17.
  12. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Inhaled Corticosteroids. Proceedings of the 17th Annual Meeting of the Graduate Research Association of Students in Pharmaceutics, Gainesville, FL, June 6-8, 1997.
  13. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Predictive Power of PK/PD-Modeling for Inhaled Corticosteroids. Journal of Clinical Pharmacology 37 (1997), p. 865.
  14. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Advanced PK/PD-model for the modulation of Lymphocyte Count by Glucocorticoids and Endogenous Cortisol. Journal of Clinical Pharmacology 37 (1997), p. 865.
  15. Möllmann, HW, Wagner, M, Stöckmann, R, Derendorf, H, Hochhaus, G, Meibohm, B, Barth, J, Krieg, M: Pharmacokinetic/Pharmacodynamic Evaluation after Single-Dose Fluticasone Propionate. Proceedings of the XVIth International Congress of Allergology & Clinical Immunology, Cancun, Mexico, October 19-24, 1997
  16. Wagner, M, Hochhaus, G, Stöckmann, R, Derendorf, H, Barth, J, Meibohm, B, Krieg, M, Möllmann, HW: Pharmacokinetics and Pharmacodynamics after Inhaled Administration of Flunisolide. Proceedings of the XVIth International Congress of Allergology & Clinical Immunology, Cancun, Mexico, October 19-24, 1997
  17. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Chronopharmacology of Cortisol Suppression during Inhaled Corticosteroid Therapy. Pharmaceutical Research 14 (1997), (suppl.), p. 141.
  18. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Absorption Profiles of Inhaled Corticosteroids. Pharmaceutical Research 14 (1997), (suppl.), p. 141.
  19. Hochhaus, G, Meibohm, B, Möllmann, H, Derendorf, H, Barth, J, Wagner, M, Krieg, M, Knoeller, J: Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Budesonide after Oral Delivery. Pharmaceutical Research 14 (1997), (suppl.), p. 617.
  20. Hochhaus, G, Derendorf, H, Meibohm, B: Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Inhaled Corticosteroids. Pharmaceutical Research 14 (1997), (suppl.), p. 140.
  21. Möllmann, H, Derendorf, H, Barth, J, Meibohm, B, Wagner, M, Krieg, M, Knoeller, J, Barth, J, Möllmann, A, Hochhaus, G: Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. Pharmaceutical Research 14 (1997), (suppl.), p. 140.
  22. Meibohm, B, Derendorf, H, Möllmann, H, Wagner, M, Fröehlich, P, Hochhaus, G: Physiologically Based PK/PD-Model for the Interaction between Endogenous and Exogenous Corticosteroids and Lymphocytes. Clinical Pharmacology and Therapeutics 63 (1998), p. 201.
  23. Hochhaus, G, Derendorf, H, Meibohm, B: Effect of Clearance and Volume of Distribution on Pulmonary Targeting of Inhaled Corticosteroids. In: Danhof, M, Steimer, JL (eds.) Measurement and Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, The Netherlands 1998, p. 155-156.
  24. Hochhaus, G, Meibohm, B, Stark, J, Möllmann, H, Derendorf, H, Wagner, M: Interaction between Endogenous and Exogenous Corticosteroids and Blood Lymphocytes: The Buffering Capacity of Cortisol Suppression. In: Danhof, M, Steimer, JL (eds.) Measurement and Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, The Netherlands 1998, p. 156-157.
  25. Meibohm, B, Derendorf, H, Möllmann, H, Wagner, M, Hochhaus, G: Mechanism Based Pharmacokinetic/Pharmacodynamic Model for the Interaction between Endogenous and Exogenous Corticosteroids and Blood Lymphocytes. In: Danhof, M, Steimer, JL (eds.) Measurement and Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, The Netherlands 1998, p. 157-158.
  26. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Derendorf, H: Chronopharmacological Aspects in Cortisol Suppression during Inhaled Corticosteroid Therapy. In: Danhof, M, Steimer, JL (eds.) Measurement and Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, The Netherlands 1998, p. 158-159.
  27. Meibohm, B, Kleine, P, Führer, C: Stereoselective Pharmacokinetic Variability of Mexiletine in Patients during Chronic Oral Therapy. PharmSci 1 (1998), (suppl.), p. S144.
  28. Behn, F, Läer, S, Scholz, H, Mir, TS, Eiselt, M, Venske, A, Weil, J, Meibohm, B: Carvedilol in Children with Congestive Heart Failure - Pharmacokinetic Parameters. Naunyn Schmiedeberg´s Arch Pharmacol 359 (1999), p. R130.
  29. Läer, S, Behn, F, Scholz, H, Mir, TS, Eiselt, M, Venske, A, Weil, J, Meibohm, B: Carvedilol in Children with Congestive Heart Failure. Eur J Clin Pharmacol 55 (1999), p. A30.
  30. Meibohm, B, Neugebauer, R, Bühring, KU, Schulte, M, Kovar, A: Pharmacokinetics of EMD 132 338 after Escalating Single Oral Doses of Gantofiban, a New Glycoprotein IIB/IIIA Receptor Antagonist. J Clin Pharmacol 39 (1999), p. 978.
  31. Meibohm, B, Schulte, M, Neugebauer, R, Kovar, A: Pharmacokinetic Modeling of the Orally Available Glycoprotein IIb/IIIa Antagonist Gantofiban in Man. PharmSci 1 (1999), #1043.
  32. Läer, S, Behn, F, Wauer, I, Hulpke-Wette, M, Mir TS, Meibohm, B: Pharmacokinetics of Sotalol in Children with Supraventricular Tachycardia. Clin Pharmacol Ther 67 (2000), P-II 63, p. 130.
  33. Behn, F, Läer, S, Scholz, H, Mir, TS, Weil, J, Meibohm, B: Heart Rate and Mean Arterial Pressure During Carvedilol Therapy in Children of Different Ages. Naunyn Schmiedeberg´s Arch Pharmacol 361 (2000), p. R123.
  34. Wauer, I, Läer, S, Behn, F, Scholz, H, Hulpke-Wette, M, Mir, TS, Weil, J, Meibohm, B. Sotalol in Pediatric Patients with Supraventricular Tachycardia: Dosage Regimens based on Body Weight or on Body Surface Area ? Eur. J. Clin Pharmacol. 56 (2000), P. A18.
  35. Meibohm, B, Brändle, M., Fluck, M., Kovar, A: Pharmacokinetic/ Pharmacodynamic Modeling of the Novel PDE-5 Inhibitor EMD 221 829 in Dogs. AAPS PharmSci 2 (2000), #2675.
  36. Zhang, W, de Armendi, AJ, Dabbs, K, Anghelescu, D, Meibohm, B: An HPLC Method for the Determination of Propofol in Small Volume Human Blood Samples. AAPS PharmSci 2 (2000), (4, Supplement) #1040.
  37. Läer, S, Behn, F, Elshoff, JP, Scholz, H, Wauer, I, Hulpke-Wette, M, Meibohm, B, Mir, TS, Weil, J. Drug Response in Pediatric Patients with Heart Disease. Naunyn Schmiedeberg´s Archives of Pharmacology 363 (2001), R117.
  38. Läer, S, Behn, F, Scholz, H, Mir, TS, Weil, J, Meibohm, B. Carvedilol in Pediatric Congestive Heart Failure: Do Young Children behave like Little Adults? Clinical Pharmacology and Therapeutics 69 (2001), p. 52.
  39. Läer, S, Wauer, I, Elshoff, JP, Meibohm, B, Scholz, H, Mir, TS, Weil J, Hulpke-Wette, M. Effects of Sotalol in Pediatric Patients: Evidence for Developmental Changes in Sotalol’s Proarrhythmic and Antiarrhythmic Action. Z Kardiol 90 (2001), II/55.
  40. Zhang, W, de Armendi, AJ, Anghelescu, DL, Meibohm, B. An HPLC Assay for the Determination of Propofol in Small Volume Blood Samples in Pediatric Anesthesia. Anesthesiology 95 (2001), A485.
  41. Gupta, M, Tang, L, Yates, CR, Tolley, EA, Wicks, MN, Freire, AX, Meibohm, B. Comparative Gene Expression Profiling of Mediators of Inflammation in COPD versus Asthma Patients: Screening for Potential Pharmacodynamic Response Markers. AAPS PharmSci 3 (2001), (4, Supplement) #T3727.
  42. Zhang, W, Elshoff, JP, Läer, S, Mir, TS, Hulpke-Wette, M, Meibohm B. Population Pharmacokinetics of Sotalol in Pediatric Patients with Tachycardia. AAPS PharmSci 3 (2001), (4, Supplement) #M2311.
  43. Larkin, AG, Meibohm, B. Comparability of Parameter Estimates Obtained from Different PK/PD Modeling Software. AAPS PharmSci 3 (2001), (4, Supplement) #M2358.
  44. Läer, S, Elshoff, JP, Scholz, H, Wauer, I, Meibohm, B, Mir, TS, Weil J, Hulpke-Wette, M. Developmental Changes in Proarrhythmic and Antiarrhythmic action of Sotalol in Children with Tachycardia. Circulation 104 (2001), (17 Suppl II), II-488/489.
  45. Läer, S, Behn, F, Scholz, H, Eiselt, M, Mir, TS, Weil J, Meibohm, B. Successful Therapy with Carvedilol in Pediatric Patients with Myocardial Failure. Circulation 104 (2001), (17 Suppl II), II-679.
  46. Yates, CR, Zhang, W, Song, P, Gaber, AO, Honaker, M, Kotb, M, Alloway, R, and Meibohm, B. Effect of CYP3A5 Genotype on Cyclosporine Disposition: A Pilot Study. Clinical Pharmacology and Therapeutics 71 (2002), P-3.
  47. Song, P, Meibohm, B, Gaber, AO, Kotb, M, and Yates, CR. Detection of MDR1 Single Nucleotide Polymorphisms (SNPs) C3435T and G2677A Using Real-time PCR. Clinical Pharmacology and Therapeutics 71 (2002), P-102.
  48. Song, P, Dirks, N, Gaber, AO, Kotb, M, Meibohm, B, Stuart, L and Yates, CR. Detection of CYP3A5*3 and *6 Using Real-time PCR. Clinical Pharmacology and Therapeutics 71 (2002), P-102.
  49. Talley, CH, Wicks, MN, Freire, AX, Tolley, EA, Meibohm, B, and Martin, JC. Correlated of Burden in Spouse Caregivers of Patients with COPD. (accepted). American Journal of Respiratory and Critical Care Medicine 165 (2002), A832.
  50. Sharma, A, Hamelin, BA, Fluck, M, Pibarot, P, Arsenault, M, Dumesnil, J, Pilote, S, Meibohm, B. Mechanism-Based PK/PD-Modeling of the Effect of Metoprolol on Cardiac Index. In: Danhof, M, Karlsson, M, Powell, RJ (eds.) Measurement and Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, The Netherlands 1998, p. 63-64.
  51. . Läer, S, Behn, F, and Meibohm, B. Developmental Pharmacodynamics of Carvedilol in Pediatric Patients with Congestive Heart Failure. In: Danhof, M, Karlsson, M, Powell, RJ (eds.) Measurement and Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, The Netherlands 1998, p. 35-37.
  52. Yates, CR, Meibohm, B, Zhang, W, Song, P, Li, S, Gaber, AO, Honaker, MR, Kotb, M and Alloway, RR. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition. Transplantation 74 (2002), V-2113.
  53. Song, P, Shukla, N, Schuetz, EG, Zamber, C, Meibohm, B, and Yates, CR. Determination of Hepatic MDR1 Expression in African-Americans and Caucasians Using Real-time PCR. AAPS PharmSci 4 (2002), (4, Supplement) #M1100.
  54. Gupta, M, Freire, AX, Griffin , JG, Headley, AH, Katancik, JA, Kritchevsky, SB, Tolley, EA, Wicks, MN, Yates, CR, Meibohm, B. Development of a Real-Time PCR Genotyping Assay for b2–Adrenergic Receptor (b2–AR) Polymorphisms. AAPS PharmSci 4 (2002), (4, Supplement) #T2244.
  55. Meibohm, B. Application of PK/PD-Concepts for Efficient Drug Development. Eur J Clin Pharmacol 58 (2002), S102.
  56. Läer, S, Elshoff, JP, Zhang, W, Meibohm, B. Population Pharmacokinetic Modeling for Sotalol in Pediatric Patients with Tachycardia. Eur J Clin Pharmacol 58 (2002), S76.
  57. Meibohm, B. Exposure-Response vs. Dose-Response Assessments in Drug Development. AGAH 2003, 2: op013. www.biomedcentral.com/browse/abstracts/AGAH/2.
  58. Meibohm, B, Zhang, W, Elshoff, JP, Behn, F, Hulpke-Wette, M, Läer, S. Population Pharmacokinetics and Pharmacodynamics of Sotalol in Infants and Children with Tachycardia. Clin Pharmacol Ther 73 (2003), P71.
  59. Läer, S, Elshoff, JP, Mir, TS, Müller-Wolf, C, Weil, J, Hulpke-Wette, M, Meibohm, B. Dosing Rationale using Population Pharmacokinetics of Sotalol in Children with Tachycardia. Naunyn Schmiedeberg´s Archives of Pharmacology 367 (2003), Suppl. R114.
  60. Meibohm, B, Gupta, M, Talley, CH, Freire, AX, Wicks, MN, Tolley, EA, Yates, CR. cDNA Array Analysis Indicates Upregulation of CXCR2 and CXCR5 Expression in COPD. Am J Respir Crit Care Med 167 (2003), A939.
  61. Christensen, M, Meibohm, B, Capparelli, E, Tamborlane W. Single and Multiple Dose Pharmacokinetics of Pioglitazone in Adolescents with Type 2 Diabetes. J Clin Pharmacol 43 (2003), p. 1038.
  62. Zhang W, Zamber, C, Song, P, Schuetz, EG, Yates, CR, Meibohm, B. Developmental Changes of Hepatic P-gp Expression in Pediatric Patients. AAPS PharmSci 5 (2003), (4, Supplement) #W4375.
  63. Gupta, M, Talley , CH. Freire, AX, Wicks, MN, Tolley, EA, Yates, CR, Meibohm, B. cDNA-Array Based Gene Expression Profiling Indicates Upregulation of Chemokine Receptors in COPD. AAPS PharmSci 5 (2003), (4, Supplement) #M1073.
  64. Toler, D, Brower, J, Buhse, L, Sadrieh, N, Machado, S, Straughn, A, Yates, R, Meibohm, B. Stability and Palatability Evaluation of Ciprofloxacin Hydrochloride Mixed with Food or Drink. AAPS PharmSci 5 (2003), (4, Supplement) #T2003.
  65. Song, P, Zhang, W, Lo, A, Meibohm, B, Yates, CR. MDR1 C3435T: Does It Affect Cyclosporine Pharmacodynamics? AAPS PharmSci 5 (2003), (4, Supplement) #W4393.
  66. Meibohm, B. How Important are Sex Differences in Pharmacokinetics? Proceedings from Understanding the Biology of Sex Differences, The Fifth Annual Conference on Sex & Gene Expression, Society for Women’s Health Research, Winston-Salem, NC, March 25-28, 2004, pp. 35-37.
  67. Tang, L, Zhang, W, Gupta, M, Zamber, C, Schuetz, EG, Meibohm, B. Ontogeny of Hepatic MDR1, MRP1, AND MRP2 Expression in Human Pediatric Liver Biopsies. J Clin Pharmacol 44 (2004), P71, p. 1202.
  68. Gupta, M, Zhang, L, Tolley, EA, Li, R, Bauer, D, Ding, J, Harris, TB, Newman, AB, Kritchevsky, SB, Meibohm B. Racial Differences in the Association of b2-AR Polymorphisms with the Prevalence and Severity of COPD. J Clin Pharmacol 44 (2004), P82, p. 1204.
  69. Tang, L, Joseph, K, Phelps, S, Meibohm, B. Vancomycin Population Pharmacokinetics in Premature and Term Neonates. AAPS J 6 (2004), (Supplement 1), #W4336.
  70. Song, P, Zhang, L, Meibohm, B, Yates, CR. A Preliminary Classification-SAR Model for Pgp Substrate Prediction. AAPS J 6 (2004), (Supplement 1), #W4119.
  71. Dirks, N, Li, S, Yates, CR, Hochhaus, G, Meibohm, B. Relative Anti-Inflammatory Potency of Corticosteroids Measured by AP-1 Inhibitory Activity. AAPS J 6 (2004), (Supplement 1), #T2055.
  72. Gupta, M, Zhang, L, Tolley, EA, Li, R, Bauer, D, Ding, J, Harris, TB, Newman, AB, Kritchevsky, SB, Meibohm B. Racial Differences in the Association of b2-AR Polymorphisms with the Frequency and Severity of COPD. AAPS J 6 (2004), (Supplement 1), #W5062.
  73. Straughn, A, Sadrieh, N, Yates, CR, Meibohm, B, Chen, M-L, Hussain, A. Effect of Sorbitol on Bioequivalence of Ranitidine Oral Solutions. AAPS J 6 (2004), (Supplement 1), #2300.
  74. Speicher, BT, Gidner, J, Freedman, R, Meibohm, B, Warren , M, Hazelwood, M, Leventerr, SM, Keogh, JC, Ye, N, Kucharik, RF, Keim, KL. The Effects of Levotofisopam, a Novel Homophthalazine, in a Phase 1B Study Designed to Demonstrate Early Signal Detection in Treatment of the Symptoms of Menopause. Menopause 11 (2004), p. 644.
  75. Laer, S, Albers, S, Gupta, M, Meibohm, B. Population Pharmacokinetics of Carvedilol in Pediatric Patients with Congestive Heart Failure. To be presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March 2-5, 2005.
  76. Tang, L, Gupta, M, Zamber, C, Schuetz, EG, Meibohm, B. Ontogeny of Various Solute Carrier Family (SLC) Transporter Expression in Human Pediatric Liver Biopsies. To be presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March 2-5, 2005.

Selected Recent Presentations

  1. Meibohm, B, Kleine, P, Führer, C: Investigations on the Stereoselective Pharmacokinetics of Mexiletine during Chronic Oral Therapy, 2nd European Congress of Pharmaceutical Sciences, Humboldt-University, Berlin, Germany, October 1, 1994
  2. Meibohm, B: Enantioselective Analytics of Racemic Drugs in Biological Matrices with Mexiletine and its Metabolites as Example, Institute of Pharmaceutical Chemistry, Technical University Carolo-Wilhelmina, Braunschweig, Germany, December 8, 1994
  3. Meibohm, B: ‘Pharmaceutical Service TPN’, Harburger Future Forum for Health, ADKA Hamburg, Hamburg, Germany, February 4, 1995
  4. Cooke, J, Meibohm, B: Pharmacoeconomy in Oncology, 4th International Symposium on Oncology Pharmacy Practice (ISOPP), Hamburg, Germany, May 5, 1995
  5. Meibohm, B, Garms, T, Meier, K, Melzer, S: Pharmacoeconomic Benefit of the Implementation of a Patient Oriented Automated Drug Distribution System in Combination with Intensive Advisory Services, 1st International Conference on New Areas in Pharmaceutical Research, Oporto, Portugal, September 21, 1995
  6. Meibohm, B: CYPRO - The Software for Compounding Cytotoxic Drugs, Baxter Healthcare, Chicago, USA, June 12, 1996
  7. Reeder, CE, Meibohm, B: ‘Designing a Pharmacoeconomic Evaluation: Principles and Methods, 5th North German Cytotoxics Workshop, Hamburg, Germany, February 8, 1997
  8. Derendorf, H, Doehring, P, Meibohm, B: Clinical Pharmacokinetics and Drug Monitoring, University of Münster, Germany, May 22-23, 1997
  9. Meibohm, B: Pharmacokinetic/Pharmacodynamic Modeling of Inhaled Corticosteroids, Oral presentation, 1st Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology, University of Münster, Germany, May 24, 1997
  10. Meibohm, B: Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Inhaled Corticosteroids, College of Pharmacy, University of South Carolina, Columbia, SC, June 5, 1997
  11. Meibohm, B: Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Inhaled Corticosteroids, The Seventeenth Annual Meeting of the Graduate Research Association of Students in Pharmaceutics (GRASP '97), University of Florida, Gainesville, Florida, June 7, 1997
  12. Meibohm, B: Differences in the Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids, University of Florida, Health Science Center, Gainesville, FL, September 25, 1997
  13. Reeder, CE, Meibohm, B: Pharmacoeconomic Analysis: Principles, Methods and Examples, 6th North German Cytotoxics Workshop, Hamburg, Germany, January 24, 1998
  14. Meibohm, B: Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling: Principles and Applications, University Hospital Eppendorf, University of Hamburg, Hamburg, Germany, May 19, 1998
  15. Meibohm, B: Pharmacokinetic Assessment of Absorption Parameters - Methods and Pitfalls, Clinical Research & Development / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, July 29, 1998
  16. Meibohm, B: Pharmacokinetic/Pharmacodynamic Modeling of Cytotoxic Drugs - Principles and Examples, Clinical Research & Development / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, July 30, 1998
  17. Meibohm, B: Concepts of Modeling Pharmacokinetic/Pharmacodynamic Relationships and their Application to Inhaled Corticosteroids, Department of Pharmaceutical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, November 5, 1998
  18. Meibohm, B: Inhaled Corticosteroid Therapy as an Example for Applied PK/PD-Modeling, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, Memphis, TN, March 9, 1999
  19. Meibohm, B: Application of PK/PD-Modeling Concepts for Cytotoxic Drugs, ASTA Medica AG, Frankfurt, Germany, June 1, 1999
  20. Meibohm, B: Classification of PK/PD-Modeling Approaches, Presentation, 2nd Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology, University of Reims - Champagne Ardenne, France, June 5, 1999
  21. Meibohm, B: ‘Dose Individualization of Cytotoxics Based on Pharmacokinetic and Pharmacodynamic Concepts’, Seminar, 8th North German Cytotoxics Workshop, Hamburg, Germany, January 29, 2000
  22. Meibohm, B: ‘Gender Differences in Pharmacokinetics and Pharmacodynamics – Do They Matter ? Seminar, Clinical R&D Operations / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, May 18, 2000
  23. Meibohm, B: ‘Update on the Clinical Pharmacology of Gantofiban’, Clinical R&D Operations / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, May 18, 2000
  24. Meibohm, B: ‘Preclinical Pharmacokinetics and Pharmacodynamics of EMD 221 829 in Dogs’, Clinical R&D Operations / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, May 19, 2000
  25. Meibohm, B: ‘Pharmacogenetics in Cancer Chemotherapy’, Seminar, 9th North German Cytotoxics Workshop, Hamburg, Germany, January 27, 2001
  26. Meibohm, B: ‘Screening for Pharmacodynamic Response Markers in COPD by cDNA-Microarrays’, Clinical R&D Operations / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, June 13, 2001
  27. Meibohm, B: ‘Pharmacokinetic/Pharmacodynamic Studies in Drug Product Development’, Clinical R&D Operations / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, June 13, 2001
  28. Meibohm, B: ‘Screening for Pharmacodynamic Response Markers in COPD by cDNA-Microarrays’, Presentation, 3rd Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology, Dresden, Germany, June 16, 2001
  29. Meibohm, B: ‘Developmental Pharmacokinetics and Pharmacodynamics in Pediatric Cardiology’, Seminar, Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, November 9, 2001.
  30. Meibohm, B: ‘Overview of Drug Transport’, Invited Presentation, 8th International Symposium on Oncology Pharmacy Practice, Vancouver, Canada, May 9, 2002.
  31. Meibohm, B: ‘P-gp Drug Interactions in Oncology’, Invited Presentation, 8th International Symposium on Oncology Pharmacy Practice, Vancouver, Canada, May 9, 2002
  32. Meibohm, B: 'Drug Transporters as a Source of Interindividual Variability in Drug Response', Seminar, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, Memphis, TN, August 26, 2002
  33. Meibohm, B: ‘Effect of MDR1 Genetic Polymorphisms on Drug Disposition’, Seminar, Clinical R&D Operations / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, November 7, 2002.
  34. Meibohm, B: ‘Application of PK/PD-Concepts for Efficient Drug Development’, Invited Presentation, VKliPha 4th Annual Congress on Clinical Pharmacology, Wiesbaden, Germany, November 9, 2002.
  35. Meibohm, B: ‘Exposure-Response vs. Dose-Response Assessments in Drug Development’, Invited Presentation, Annual Congress of the Association for Applied Human Pharmacology (AGAH), Bonn, Germany, February 23-25, 2003.
  36. Meibohm, B, Gupta, M, Freire, AX, Wicks, MN, Tolley, EA, Yates, CR. ‘cDNA Array Analysis Indicates Upregulation of CXCR2 and CXCR5 Expression in COPD’, Contributed Paper Presentation, 99th International Conference, American Thoracic Society, Seattle, WA, May 21, 2003.
  37. Meibohm, B: ‘Molecular & Genetic Factors in COPD’, Invited Lecture, Pulmonary Medicine Series – Obstructive and Genetic Lung Diseases, University of Tennessee College of Medicine , Division of Pulmonary & Critical Care Medicine, Memphis, TN, September 9, 2003.
  38. Meibohm, B: ‘Pharmacokinetics and Pharmacodynamics in Drug Dose Administration Schemes', Visiting Professorship, 90. Nephrology Forum Munich, Ludwig-Maximilians-University, Munich, Germany, November 24, 2003.
  39. Meibohm, B: ‘How Important are Sex Differences in Pharmacokinetics?', Invited Presentation, Fifth Annual Conference on Sex and Gene Expression (SAGE V), Society for Women’s Health Research, Graylyn Conference Center, Winston-Salem, NC, March 27, 2004.
  40. Meibohm, B: ‘Introduction to PK/PD-Modeling’, Seminar, Clinical Pharmacokinetics / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, April 21, 2004.
  41. Meibohm, B: ‘How Important are Sex Differences in Pharmacokinetics?’, Seminar, Clinical Pharmacokinetics / Clinical Pharmacology, Merck KGaA, Darmstadt, Germany, April 22, 2004.
  42. Meibohm, B: ‘Pharmacokinetics of Oligonucleotides’, Invited Presentation, VKliPha 9th Annual PK/PD Expert Meeting, Freiburg, Germany, April 24, 2004.
  43. Meibohm, B: ‘PK/PD Modeling as the Basis for the Development and Validation of Biomarkers’, Invited Presentation, AAPS Workshop: Clinical Biomarkers in Drug Development: Efficacy Assessment, Pharmacokinetics/Pharmacodynamics and Regulatory Insights, Baltimore, MD, November 5, 2004.
  44. Meibohm, B: ‘Developmental Changes in Molecular Mechanisms of Pediatric Drug Disposition’, Oral Presentation, 5th Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology, Leuven, Belgium, June 4, 2005
  45. Meibohm, B: ‘Clinical Pharmacology and Pharmacy of Oligonucleotides Drug Candidates’, PharmSciFair Pharmaceutical Sciences Fair & Exhibition, Nice, France , June 13, 2005
  46. Meibohm, B: ‘Biomarkers in Pharmacokinetic/Pharmacodynamic Modeling to Integrate Expose/Response’, AAPS Workshop: Integrated Roadmap to Biomarker for Drug Development – Method Validation and Qualification, Rockville , MD , September 9, 2005
  47. Meibohm, B: ‘Population Pharmacokinetic Studies: Issues in Design and Analysis’, Johnson& Johnson Pediatrics Symposium – Not Just Child’s Play: The Impact of Modeling & Simulation in Pediatric Drug Development, Bridgewater, NJ, October 17, 2005
  48. Meibohm, B: ‘Introduction to Modeling & Simulation 101’, American Association of Pharmaceutical Scientists AAPS 2006 Annual Meeting, Nashville , TN , November 6, 2005.
  49. Meibohm, B: ‘Applying Biological Rhythms in Timing of Medication: Glucocorticoids as an Example’, Neuroendocrine Immunology Study Group, American College of Rheumatology ACR 69th/ARHP 40th Annual Scientific Meeting, San Diego, CA, November 14, 2005.
  50. Meibohm, B: ‘Evaluation of Pharmacokinetic Metrics for a Pharmacogenetic Study’, Association for Applied Human Pharmacology/American College of Clinical Pharmacology AGAH/ACCP Workshop on Computer Simulation and its Role in Drug Development, Düsseldorf , Germany , February 19, 2006.
  51. Meibohm, B: ‘Interplay between Drug Metabolizing Enzymes and Drug Transporters’, Association for Applied Human Pharmacology/American College of Clinical Pharmacology AGAH/ACCP 2nd Joint Meeting – Transatlantic Strategies in Early Drug Development, Düsseldorf, Germany, February 20, 2006
  52. Meibohm, B: ‘Developmental Changes in Pediatric Drug Disposition and Response’, Pfizer Lecture Series, Department of Pharmaceutical Sciences, University of Michigan College of Pharmacy , Ann Arbor , MI , March 22, 2006.
  53. Meibohm, B: ‘Biomarkers and PK/PD Modeling: A Match Made in Heaven!’, Pfizer Inc. Global Research & Development, Ann Arbor, MI, March 23, 2006.
  54. Meibohm, B: ‘Biomarkers as Prerequisite for PK/PD Modeling and Model-Based Drug Development’, Clinical Biomarker Summit, Cambridge Healthtech Institute, San Diego , CA , March 30, 2006.